NJ-OPEX/VANAS
30.11.2021 13:02:11 CET | Business Wire | Press release
OPEX® Corporation , a global provider of innovative warehouse, document and mail automation solutions, has entered into a new partnership with Vanas Engineering , a leading provider of intralogistics warehouse solutions and software that will help customers throughout Belgium, the Netherlands and Luxembourg (Benelux) identify and install the most efficient and productive warehouse management solutions for its businesses. The terms of the agreement are not public.
“OPEX was looking for a strong partner to expand our reach in Benelux, a target market for our products and services,” said Nicolas Dewit, Warehouse Automation Director of Business Development for OPEX Europe, Middle East and Africa (EMEA). “The people at Vanas are experts at intralogistics warehouse solutions and in helping their customers find innovative technology to propel their business forward. That customer-centric approach matches our own. Together, we are excited to provide a seamless solution for automation that maximizes warehouse space, and manages peaks and demands, without additional labor.”
OPEX offers dynamic eCommerce fulfillment solutions that utilize scalable warehouse robots to provide speed and accuracy, and streamline the supply chain from inventory storage and picking to sorting and shipping.
In addition, OPEX provides micro-fulfillment technology that optimizes space and helps execute flawless last-mile delivery, and offers reverse logistics solutions that improve returns, exchange operations and revenue with maximum speed and reduced labor.
“We are constantly looking for new technologies that can raise performances and bring added value to our customers,” said Andy Van Mieghem, Managing Director, Vanas Engineering. “OPEX delivers value, using unique innovative technology called iBOT® robotic vehicles, which we see benefitting our customers. The Perfect Pick® solution will bring a strong picking and retrieval system to the Benelux region that includes picking stations with speeds up to 500 order lines per pick station, while the Sure Sort® is a unique vertical sorting system which fits in a very small footprint.”
Mieghem adds, “I’m convinced that by offering OPEX solutions, this will encourage several of our customers in Benelux to automate. The fact that it’s a proven technology for years in the USA generates confidence for us as an integrator and for our end-customers.”
OPEX also offers document and mail automation solutions that offer seamless and secure mail sorting , document imaging and payment processing to improve business workflow and throughput, while reducing or eliminating intensive document preparation.
About
OPEX Corporation provides Next Generation Automation, including warehouse, document and mail automation solutions, to customers around the globe. With headquarters in Moorestown, NJ―and facilities in Pennsauken, NJ; Plano, TX (Dallas metro); France; Germany; Switzerland; and the United Kingdom―OPEX has more than 1,450 employees committed to reimagining and delivering innovative, scalable, unique technology solutions to solve the business challenges of today.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211130005406/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Danish C-UAS Startup Shotling Raises €700K Oversubscribed Pre-Seed (Myriad-IPO CLUB-EIFO) for Anti-Drone Shotgun2.2.2026 07:35:00 CET | Press release
Shotling, a Danish defense technology startup specializing in kinetic short-range counter-UAS (C-UAS) systems, today announced the closing of a pre-seed financing round with €700K committed out of a targeted €500K. The round is led by Myriad Defense Fund, with co-investment from IPO CLUB’s Fund II America 2030, and a non-dilutive match-loan granted by EIFO, the Export and Investment Fund of Denmark, supporting Shotling’s mission to deliver rapid-fire modular shotgun systems against FPV drones and loitering munitions—as the global counter-UAS market accelerates towards $10B by 2030, with kinetic defense segment showing strong momentum (25%+ CAGR). Shotling’s rotary shotgun system provides unmatched close-range defense (50–100m) against the rapidly growing threat of kamikaze drones, combining a gatling-style design, with novel, high-capacity magazines, and firing rates up to 3,000 RPM using standard or tungsten-based 12-gauge shells. With deep expertise in weapons engineering and active
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults RelabotulinumtoxinA is designed to optimize molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for frown lines and crow’s feet and has been approved in over 20 markets, including in the European Union1-3 Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation
High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 08:00:00 CET | Press release
Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom